NxThera is a technology company.
NxThera has raised $22.0M across 1 funding round.
NxThera has raised $22.0M in total across 1 funding round.
NxThera has raised $22.0M in total across 1 funding round.
NxThera's investors include Arboretum Ventures, Perseverance Capital, Shane Neman.
NxThera is a medical technology company that developed the Convective Water Vapor Energy (WAVE) platform, including the FDA-cleared Rezūm System, a minimally invasive treatment for benign prostatic hyperplasia (BPH) using steam to deliver targeted thermal energy, improving lower urinary tract symptoms (LUTS), urine flow, and quality of life with minimal discomfort.[1][3][4] It serves urologists and patients with endourological conditions like BPH, prostate cancer, and kidney cancer, addressing problems such as painful symptoms, sexual dysfunction risks from traditional treatments (e.g., surgery or drugs), and high recovery times by enabling same-day procedures and quick return to normal activities.[1][4][5] The company showed strong growth, securing FDA clearance for Rezūm in 2015, expanding commercially in the US and Europe, and culminating in its 2018 acquisition by Boston Scientific for $306 million upfront plus up to $100 million in milestones, integrating it into a leading urology portfolio.[5]
NxThera was founded in June 2008 by Michael Hoey in Maple Grove, Minnesota, to pioneer water vapor technology for urology advancements.[4] Hoey, with a background in medical device innovation, drove the development of the WAVE platform starting with BPH treatments.[2][4] Key milestones included FDA clearance for the Rezūm System in August 2015, enabling in-office BPH procedures, followed by commercialization in the US and Europe, and leadership under CEO Bob Paulson, who highlighted partnerships like the Boston Scientific acquisition in 2018 as pivotal for broader access.[4][5]
NxThera rode the trend toward minimally invasive urology therapies, capitalizing on growing BPH prevalence (affecting millions of aging men) and demand for alternatives to pharmaceuticals with side effects or invasive surgeries.[1][5] Timing was ideal amid 2010s medtech shifts to outpatient procedures reducing costs and hospital stays, with market forces like rising healthcare efficiency pressures favoring quick-recovery innovations.[5][6] Its WAVE platform influenced the ecosystem by validating water vapor ablation, inspiring expansions to cancers (e.g., Francis Medical's Vanquish system targeting prostate/kidney/bladder), and strengthening Boston Scientific's dominance in urology/pelvic health post-2018 acquisition.[4][5]
Post-acquisition, NxThera's Rezūm technology continues scaling within Boston Scientific, with successor platforms like Francis Medical's pursuing FDA clearance for prostate cancer ablation by late 2025, promising fewer side effects than traditional options.[4] Trends in precision medtech, aging populations, and outpatient shifts will propel water vapor therapies, potentially expanding to global markets and broader endourological cancers.[1][4] Its legacy elevates minimally invasive BPH care, setting a benchmark for thermal energy innovations that prioritize patient quality of life from the outset.[5]
NxThera has raised $22.0M across 1 funding round. Most recently, it raised $22.0M Series B in October 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2011 | $22.0M Series B | Arboretum Ventures, Perseverance Capital, Shane Neman |